Efalizumab-induced immune thrombocytopenia during retreatment - 01/11/17
Doi : 10.1016/j.jaad.2007.07.025
Maria Concetta Fargnoli, MD a, Antonio Tabilio, MD b, Gino Coletti, MD c, Ketty Peris, MD a, ⁎ 
a Department of Dermatology, University of L’Aquila, Italy
b Department of Internal Medicine and Public Health, University of L’Aquila, Italy
c Department of Pathology, Ospedale San Salvatore, ASL-04, L’Aquila, Italy
Correspondence to: Ketty Peris, MD, Department of Dermatology, University of L’Aquila, Via Vetoio-Coppito 2, 67100 L’Aquila, Italy.| Funding sources: None. |
|
| Disclosure: Dr Peris has acted as paid speaker for Merck Serono. Drs Fargnoli, Tabilio, and Coletti have no conflicts of interest to declare. |
|
| Reprints not available from the authors. |
© 2008
American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 58 - N° 5S1
P. S125-S127 - mai 2008 Retour au numéro
Article précédent
- Synchronous verrucous carcinoma and cutaneous T-cell lymphoma
- Amy C. Parsons, Daniel J. Sheehan, Omar P. Sangüeza
- Discordant response to rituximab in a systemic sclerosis patient with associated myositis
- Mario Fabri, Nicolas Hunzelmann, Thomas Krieg, Andrea Rubbert
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?